Dose Cancer Research Results

Dose, Dosage: Click to Expand ⟱
Source:
Type:
Drug dosage vs efficacy, and actual dosage number of research papers.
RCC, Renal cell Carcinoma: Click to Expand ⟱
Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system, accounting for 80–90% of kidney neoplasms.
The activation of the mTOR pathway has been found in RCC and is correlated with high grade and poor prognostic patient features (41,42).
Scientific Papers found: Click to Expand⟱
5740- Buty,    A Review of Nutritional Regulation of Intestinal Butyrate Synthesis: Interactions Between Dietary Polysaccharides and Proteins
- Review, RCC, NA
*eff↓, Dose↝, eff↑, HDAC↓, ac‑H3↓, ac‑H4↓, *HCAR2↑, *Inflam↓, *ROS↓, *NRF2↑, *GSH↑, *CLDN1↑, *ZO-1↑, IL1β↓, IL6↓, COX2/PTGS2↓, eff↝, eff↑, other↝,
8128- LF,    Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma
- Trial, RCC, NA
Imm↑, NK cell↑, Dose↝, toxicity↓, PFS↑,
7707- NIV,  lpi,    Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
- Trial, RCC, NA
OS↑, Dose↝,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

PFS↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ac‑H3↓, 1,   ac‑H4↓, 1,   other↝, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

HDAC↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IL1β↓, 1,   IL6↓, 1,   Imm↑, 1,   NK cell↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 3,   eff↑, 2,   eff↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

OS↑, 1,   toxicity↓, 1,  
Total Targets: 16

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

GSH↑, 1,   NRF2↑, 1,   ROS↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HCAR2↑, 1,  

Migration(tgid=13) ⓘ

CLDN1↑, 1,   ZO-1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

HCAR2↑, 1,   Inflam↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↓, 1,  
Total Targets: 9

Scientific Paper Hit Count for: Dose, Dosage
1 Butyrate
1 Lactoferrin/Talactoferrin
1 nivolumab
1 ipilimumab
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:24  Cells:%  prod#:%  Target#:1114  State#:%  Dir#:4
  wNotes=0  sortOrder:rid,rpid

 

Home Page